Published date: 16 July 2018

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 29 March 2018

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

Any region

Value of contract

£72,000,000

Procurement reference

tender_164721/687468

Published date

16 July 2018

Closing date

29 March 2018

Contract start date

1 July 2018

Contract end date

30 June 2019

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

NHS Framework Agreement for the supply of Icatibant and C1-Esterase products for the treatment of Hereditary Angioedema. The framework will commence on 1st July 2018 for a period of 12 months until 30th June 2019, with options to extend up to a further 36 months.

More information

Previous notice about this procurement

NHS Framework - Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

  • Opportunity
  • Published 27 February 2018

Attachments

Award information

Awarded date

20 June 2018

Contract start date

1 July 2018

Contract end date

30 June 2019

Total value of contract

£72,000,000

This contract was awarded to 3 suppliers.

Shire Pharmaceuticals Ltd

Address

1 Kingdom Street, London, W2 6BD

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

CSL Behring UK Limited

Address

4 Milton Road, Haywards Heath, West Sussex, RH16 1AH, UNITED KINGDOM

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

Pharming Technologies NV

Address

Darwinweg 24 , Leiden, Zuid-Holland, 2333CR Leiden, NETHERLANDS

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

About the buyer

Address

2nd Floor, Rutland House,
Runcorn
WA7 2ES
England

Email

philip.grieve@nhs.net